- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Biologic Switching and Discontinuation in Patients With Rheumatoid Arthritis
More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services.
More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services.
The study included 1794 patients who were treated with biologics; 77% of the patients were women. Results showed that 1168 patients either switched treatment or discontinued treatment.1 On average, the first switch from a biologic occurred after 269 days of treatment and discontinuation occurred after 197 days of treatment. A rheumatologist prescribed more than 80% of these first switches. Of the 222 patients who switched biologics at least once, 71 switched a second time and 15 switched a third time. “Further studies are needed to investigate the reasons for biologic switching and discontinuation and the consequent impact on clinical and economic outcomes,” concluded the authors.
References:
Reference
1. Carter CT, Tang B, Buysman E, Piech CT. Two-year longitudinal study of biologic switching and discontinuation among rheumatoid arthritis patients in a health plan. Presented at: Academy of Managed Care Pharmacy 22nd Annual Meeting and Showcase; April 9-10, 2010; San Diego.
Primary Viewpoints Episode 7: Antidepressants for Back Pain, Osteoarthritis Pain
February 25th 2021Listen to our newest podcast episode where the lead author of a recent meta-analysis shares his findings on the safety and efficacy of antidepressant medications to treat back and osteoarthritis pain.
Podcast: Arthritis, Anxiety, and Depression: Managing a Common Comorbidity
May 14th 2012Anxiety is even more common than depression among people who have arthritis, a new study has shown. Here to discuss the implications for diagnosis and treatment is Eilzabeth Lin MD, a family medicine physician who is a longstanding researcher in the field of depression and pain.
